PR Newswire
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
📈
AI Sentiment
Highly Positive
9/10
- Home
- PAVM
PAVM
PAVmed Inc.
as of 12-12-2025 3:37pm EST
$0.33
$0.02
-4.46%
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Chart Type:
Time Range:
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 9.3M | IPO Year: | 2016 |
| Target Price: | $17.00 | AVG Volume (30 days): | 412.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $0.90 | Next Earning Date: | 11-13-2025 |
| Revenue: | $29,000 | Revenue Growth: | -99.28% |
| Revenue Growth (this year): | -96.97% | Revenue Growth (next year): | 450.56% |
AI-Powered PAVM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.83%
73.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest PAVmed Inc. News
PAVM Breaking Stock News: Dive into PAVM Ticker-Specific Updates for Smart Investing
Compare PAVM vs Leading Stocks
See how PAVM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PAVM PAVmed Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.